The Parker H. Petit Distinguished Lecture Series is held each fall at the Parker H. Petit Institute for Bioengineering and Bioscience. The Distinguished Lecture Series brings nationally and internationally recognized bioengineering and bioscience leaders to the Petit Institute community to give their perspective on the future of biotechnology. Since the series began in 2002, the Petit Institute has had the distinct honor and pleasure of hosting world-renowned lecturers.
Please join us for our next Distinguished Lecture:
"Learning to Program Cellular Machines: Harnessing Cells to Treat Disease, Build Tissues, and Elucidate Design Principles"
Wendell Lim, Ph.D.
Professor of Cellular and Molecular Pharmacology
Biochemistry and Biophysics and Pharmaceutical Chemistry
Investigator, Howard Hughes Medical Institute
Byers Distinguished Professorship
University of California San Francisco
Date: October 22, 2019
Time: 11:00 a.m. - 1 p.m.
Location: Parker H. Petit Institute for
Bioengineering & Bioscience, Atrium
Wendell Lim is the Byers Distinguished Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco, and an Investigator of the Howard Hughes Medical Institute. He received his A.B. in Chemistry, summa cum laude, from Harvard College, his Ph.D. in Biochemistry and Biophysics at the Massachusetts Institute of Technology and completed his postdoctoral training at Yale University. His research focuses on the design principles of molecular circuits that govern cell decision-making and responses. His lab has made contributions in understanding the molecular machinery of cell signaling and how molecular modules have been used in evolution to build novel new behaviors. Most recently he has been a pioneer in the emerging field of synthetic biology, exploring how these design principles can be harnessed to engineer cells with customized therapeutic response programs. He is an author of the textbook, Cell Signaling (Garland Science 2014) and was the founder of the cell therapy biotech startup, Cell Design Labs, which was acquired by Gilead Biosciences in 2017.